Question follow-through · 24963
Sickle Cell Diseases: Prescriptions
To ask the Secretary of State for Health and Social Care, what estimate her Department has made of the cost to the public purse of adding sickle cell disease to the list of medical conditions conferring exemption from prescription charges; and what estima
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 28 Aug 2026
- Target answer date
- 2 Sept 2026
- Answer
- 9 Sept 2026 · 12 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
28 Aug 2026
Question tabled
To ask the Secretary of State for Health and Social Care, what estimate her Department has made of the cost to the public purse of adding sickle cell disease to the list of medical conditions conferring exemption from prescription charges; and what estima
2 Sept 2026
Target answer date
Date supplied by the official written-questions record.
9 Sept 2026
Answer published
I refer the Hon Member to the answer provided to the Hon Member for North Devon on 18 August in response to Question 18253.No specific estimates regarding this matter have been made.
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
No later same-department questions indexed.
This is an absence in covered public data, not evidence that no follow-up occurred elsewhere.